It was known that patients treated with insulin were at a higher risk of hypoglycemia, which can increase macrovascular events and mortality.[30,31] The results of our study finally indicated that SGLT2 inhibitors achieved glycemic control without increasing the incidence of hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.